Avalyn Pharma Inc. (AVLN) vs Taysha Gene Therapies, Inc. (TSHA)

Avalyn Pharma Inc. and Taysha Gene Therapies, Inc. are both Biotechnology companies. Avalyn Pharma Inc. and Taysha Gene Therapies, Inc. are of similar size ($1.3B and $1.2B). Across the 8 metrics below, Avalyn Pharma Inc. leads on 6 and Taysha Gene Therapies, Inc. on 2.

Valuation

Metric AVLN TSHA Biotechnology median
P/E n/m n/m 10.01
P/S n/m 138.07 9.02
P/B 3.34 4.56 2.13
Price to free cash flow n/m n/m 24.99
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 106.23 9.01
Earnings yield (157.17%) (10.63%) (34.01%)
Free cash flow yield (8.11%) (8.88%) (24.62%)

Profitability

Metric AVLN TSHA Biotechnology median
Gross margin — 100.00% 70.18%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (54.18%) (50.72%)
Return on assets 0.00% (41.52%) (45.56%)
Return on invested capital (127.60%) 0.00% 0.00%

Growth

Metric AVLN TSHA Biotechnology median
Revenue growth (TTM) — 18.96% 7.42%
EPS growth (last fiscal year) — 5.56% 29.36%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AVLN TSHA Biotechnology median
Debt to equity 0.04 0.13 0.00
Current ratio 25.76 18.56 4.72
Net debt to EBITDA — 2.47 1.01

Dividend

Metric AVLN TSHA Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric AVLN TSHA Biotechnology median
Market cap 1.24b 1.30b 157.22m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack